International Cooperative Study Group on Hepatocellular Carcinoma, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ann Surg Oncol. 2013 Apr;20(4):1223-9. doi: 10.1245/s10434-012-2739-y. Epub 2012 Nov 21.
Excellent long-term outcomes have been reported recently for patients with small (≤2 cm) hepatocellular carcinoma (HCC). However, the significance of microvascular invasion (MVI) in small HCC remains unclear. The purpose of this study was to determine the impact of MVI in small HCC up to 2 cm.
In 1,109 patients with solitary HCC from six major international hepatobiliary centers, the impact of MVI on long-term survival in patients with small HCC (≤2 cm) and patients with tumors larger than 2 cm was analyzed.
In patients with small HCC, long-term survival was not affected by MVI (p = 0.8), whereas in patients with larger HCC, significantly worse survival was observed in patients with MVI (p < 0.0001). In multivariate analysis, MVI (hazard ratio [HR] 1.59; 95 % confidence interval (CI) 1.27-1.99; p < 0.001), elevated alpha-fetoprotein (HR 1.41; 95 % CI 1.11-1.8; p = 0.005), and higher histologic grade (HR 1.29; 95 % CI 1.01-1.64; p = 0.04) were significant predictors of worse survival in patients with HCC larger than 2 cm but were not correlated with long-term survival in small HCC. When the cohort was divided into three groups-HCC ≤2, >2 cm without MVI, and HCC >2 cm with MVI-significant between-group survival difference was observed (p < 0.0001).
Small HCC is associated with an excellent prognosis that is not affected by the presence of MVI. The discriminatory power of the 7th edition of the AJCC classification for solitary HCC could be further improved by subdividing tumors according to size (≤2 vs. >2 cm).
最近有研究报道称,直径较小(≤2cm)的肝细胞癌(HCC)患者的长期预后良好。然而,微血管侵犯(MVI)在小 HCC 中的意义仍不明确。本研究旨在探讨 MVI 对直径≤2cm 小 HCC 患者的长期生存的影响。
在来自六个国际肝胆中心的 1109 例单发 HCC 患者中,分析了 MVI 对小 HCC(≤2cm)和大 HCC(>2cm)患者长期生存的影响。
在小 HCC 患者中,MVI 并不影响长期生存(p=0.8),而在大 HCC 患者中,MVI 患者的生存明显较差(p<0.0001)。多因素分析显示,MVI(危险比[HR] 1.59;95%置信区间[CI] 1.27-1.99;p<0.001)、甲胎蛋白升高(HR 1.41;95%CI 1.11-1.8;p=0.005)和组织学分级较高(HR 1.29;95%CI 1.01-1.64;p=0.04)是大 HCC 患者生存较差的独立预测因素,但与小 HCC 患者的长期生存无关。当将队列分为三组 HCC≤2cm、>2cm 无 MVI 和>2cm 伴 MVI 时,观察到组间生存差异具有统计学意义(p<0.0001)。
小 HCC 患者的预后良好,与 MVI 的存在无关。根据大小(≤2cm 与>2cm)对第 7 版 AJCC 分期的单发 HCC 进行细分,可进一步提高其对肿瘤的区分能力。